http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102006016991-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75260d0e739ee57dc87a119e150d87d3
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
filingDate 2006-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e8350a621f9924f3d7d7e4cedbe6f0d
publicationDate 2007-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber DE-102006016991-A1
titleOfInvention Use of kappa opioid receptor antagonists for the treatment of dissociative disorders
abstract ThenThe invention relates to the use of one or more kappa opioid receptor antagonistsnfor the treatment of dissociative disorders or for the productionna drug for the treatment of dissociative disorders.nThe invention further relates to a medicament containing twonor more kappa opioid receptor antagonists, as well as a methodnfor the preparation of the drug.
priorityDate 2006-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0249643-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9956146
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494948
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8082
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419589033
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62223
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558919
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5459845
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393625
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453754419
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468333647
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID423169493
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8172
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID160323372
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID115077
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419488529
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24847760
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419591521
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451917444
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467301926
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419496667
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590006
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5480230
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468136480
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5957728

Total number of triples: 39.